Polycystic Ovary Syndrome (PCOS), a condition affecting approximately 170 million women worldwide and one in eight women, has officially been renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change comes after a significant global consensus to address the inaccuracies surrounding the term PCOS, which many experts deemed misleading and inadequate in reflecting the complexity of the condition. The new name aims to enhance diagnostic practices and treatment options for the millions affected by this common hormonal disorder. Health professionals believe that this rebranding will lead to improved awareness and care, ultimately supporting better health outcomes for women struggling with PMOS. Experts emphasize the importance of this change, particularly in reducing the risk of misdiagnosis and improving overall management of the syndrome.